Position in RNA
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$199,921
New position
Shares Held
14,953
first reported quarter
Ownership
0.087%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 21%
Shared 0%
None 79%
Position in Biotechnology
Healthcare · as of Mar 31, 2026RHUMBLINE ADVISERS holds $1,237,848,251 across 287 Biotechnology names. RNA ranks #203 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
423,140 | $188,948,935 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
157,781 | $121,907,911 | |
| 3 | INCY |
Incyte Corp
|
693,665 | $65,287,749 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
195,277 | $64,611,300 | |
| 5 | INSM |
INSMED Inc
|
272,615 | $44,578,004 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
164,542 | $31,106,665 | |
| 7 | EXEL |
Exelixis, Inc.
|
723,931 | $31,049,400 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
1,113,266 | $30,837,468 |
All Filings in RNA
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $199,921 | 14,953 | Shares | Sole | 2026-05-12 | |
| No filing history on record for this holder in this stock. | ||||||